Step 1 of 2
TYK2 inhibitors provide a targeted approach to plaque psoriasis by selectively modulating signaling pathways within the IL-23/IL-17 axis, a key driver of disease pathogenesis. Use these downloadable slides to gain expert insights on emerging data presented at the AAD 2026 Annual Meeting and the evolving role of TYK2 inhibition in moderate to severe plaque psoriasis. Explore how next-generation TYK2 inhibitors may offer faster and deeper responses compared with deucravacitinib and potentially reshape the treatment landscape. Consider how these findings may inform future clinical decision-making.